Cefotaxime Sodium Powder for Solution Shortage: Current Status and Manufacturer Updates

Source: FDA · United States

Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Cefotaxime Sodium Powder for Solution is currently in shortage due to increased demand, with Hikma Pharmaceuticals reporting total unavailability across all presentations.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Cefotaxime Sodium.

What's in Shortage

Drug Name: Cefotaxime Sodium Powder, for Solution (Brand Name: CEFOTAXIME) Dosage Form: Powder, For Solution Therapeutic Category: Anti-Infective, Pediatric Current Status: Current Shortage

Which Manufacturers Are Affected

Hikma Pharmaceuticals USA, Inc.

  • Status: Unavailable
  • Notes: Shortage duration is unknown at this time.
  • Affected Presentations:
    • Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)
    • Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)
    • Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)
    • Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)
  • Contact Information: 800-631-2174

Why There's a Shortage

The FDA reports that the shortage of Cefotaxime Sodium is due to a demand increase for the drug.

What Patients Should Do

If you or your child are prescribed this medication, please take the following steps:

  • Consult Your Healthcare Provider: Discuss the shortage with your doctor to determine the best course of action for treatment.
  • Talk to Your Pharmacist: Pharmacists may have information on local stock or potential alternatives.
  • Contact the Manufacturer: You can reach Hikma Pharmaceuticals at 800-631-2174 for the most recent updates on availability.

Disclaimer: Patients should always consult their healthcare provider for medical advice and treatment options. Do not change or stop medication without professional guidance.

Source

Information provided by the FDA Drug Shortage Database.

  • Initial Posting Date: 02/17/2015
  • Last Updated: 03/12/2026

Original source: FDA Official Notice ↗

All Drug Shortages →

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
Cefotaxime Sodium Powder for Solution is currently in shortage due to increased demand, with Hikma Pharmaceuticals reporting total unavailability across all presentations.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.